VYKAT XR is NOT indicated for mental health disorders in Prader-Willi syndrome
VYKAT XR (diazoxide choline extended-release) is FDA-approved exclusively for treating hyperphagia in Prader-Willi syndrome—it has no approved indication for depression, anxiety, or psychosis, and should not be used for these conditions 1.
FDA-Approved Indication
The FDA label is explicit: VYKAT XR is indicated solely "for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS)" 1. There is no mention of psychiatric or mental health indications in the prescribing information 1.
Appropriate Treatment for Mental Health Disorders in PWS
For psychiatric comorbidities in patients with Prader-Willi syndrome, follow evidence-based guidelines for treating mental health disorders in patients with intellectual/developmental disabilities:
Depression and Anxiety
- SSRIs (fluoxetine, sertraline) remain first-line treatment for depression and anxiety in children and adults with intellectual disabilities, including PWS 2
- These medications have established efficacy in typically developing youth and are recommended for this population
- Benzodiazepines should be avoided for chronic anxiety due to heightened risk of behavioral disinhibition 2
Psychosis
- Atypical antipsychotics (risperidone, aripiprazole) are preferred over first-generation antipsychotics for psychotic disorders in patients with intellectual disabilities 2
- PWS-associated psychosis has unique characteristics that differ from schizophrenia and may be treatment-resistant 3
- Avoid haloperidol and other first-generation agents due to increased sensitivity to extrapyramidal symptoms in this population 2
Mood Stabilizers for Mania
- Valproic acid and lithium are appropriate for bipolar disorder in PWS patients, following the same approach as in patients without intellectual disabilities 2
Clinical Context
While VYKAT XR demonstrates benefits for hyperphagia and associated behavioral improvements (aggression, anxiety, compulsivity) in clinical trials 4, 5, 6, these are secondary effects related to improved appetite control—not direct psychiatric treatment. The medication's mechanism targets metabolic pathways, not neurotransmitter systems involved in primary psychiatric disorders.
Psychiatric manifestations occur in 44-89% of PWS patients 3, requiring dedicated psychiatric management separate from hyperphagia treatment. Behavioral interventions and environmental controls should complement pharmacotherapy 3.
Critical Safety Considerations
VYKAT XR carries significant risks that require monitoring:
- Hyperglycemia (including diabetic ketoacidosis risk)
- Fluid overload and edema
- Requires baseline and ongoing glucose/HbA1c monitoring 1
These risks are only justified when treating the approved indication (hyperphagia), not for off-label psychiatric use where safer, evidence-based alternatives exist.